Rakuten Medical, Inc.
52 articles about Rakuten Medical, Inc.
-
Show me the money! This week's who's who of IPOs and financing rounds in the biopharma world.
-
Rakuten Medical, Inc. Closes $166 Million Series D Financing led by General Catalyst
7/29/2021
Financing will support Rakuten Medical's ongoing trials of ASP-1929 in several oncologic indications and research and development of additional pipeline therapies being developed using the Illuminox™ platform.
-
Three major pharmaceutical and biotechnology companies announce the success of their respective funding rounds to support future efforts.
-
Rakuten Medical to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021
1/8/2021
Rakuten Medical, Inc., a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually January 11-14, 2021.
-
Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
12/23/2020
Rakuten Medical, Inc. announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors has enrolled and treated its first patient in the United States, at The University of Texas MD Anderson Cancer Center, Houston, Texas.
-
Rakuten Medical Japan Announces Marketing Approval of Akalux® IV Infusion 250mg and BioBlade® Laser System from the Ministry of Labour, Health and Welfare in Japan for Locoregional Cancer Treatment
9/25/2020
Rakuten Medical Inc. is proud to announce that its wholly owned subsidiary Rakuten Medical Japan K.K. has received marketing approval in Japan from the Ministry of Health, Labour and Welfare for Akalux® IV Infusion 250mg (cetuximab saratolacan sodium) to treat unresectable locally advanced or recurrent head and neck cancer.
-
Rakuten Medical Announces Acquisition of Medlight SA
8/19/2020
Rakuten Medical, Inc. announced today the acquisition of Medlight SA. Medlight produces and commercializes a large range of catheters and diffusers for optical light delivery. The terms of
-
Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical's ASP-1929 antibody-drug conjugate
7/7/2020
Rakuten Medical, Inc. (Rakuten Medical) announced they have entered a multi-year deal with Merck KGaA, Darmstadt, Germany under which Merck KGaA, Darmstadt, Germany will provide cetuximab to Rakuten Medical for its ASP-1929 program. Rakuten Medical uses cetuximab in an intermediate form as the antibody component in its product c
-
Rakuten Medical Receives Conditional Early Approval Designation from Japanese Health Ministry for its Lead Drug, ASP-1929, to Treat Recurrent Head & Neck Cancer
6/29/2020
Rakuten Medical, Inc. (Rakuten Medical) today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has notified Rakuten Medical that its lead drug ASP-1929 will be reviewed under the Conditional Early Approval System (CEAS). Compared to standard review the CEAS speeds up the approval process, bringing potentia
-
Rakuten Medical Presents Data Characterizing how Photoimmunotherapy Induces Cancer Cell Death and Enhances the Immune Response Preclinically
6/22/2020
Rakuten Medical, Inc. (Rakuten Medical) today announced the results of two preclinical studies presented at the American Association for Cancer Research (AACR) Virtual Meeting II. These studies further demonstrate t
-
Rakuten Medical and MD Anderson Announce Strategic Alliance to Advance Illuminox Platform for Cancer Treatments
6/4/2020
Rakuten Medical, Inc. (Rakuten Medical) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical's proprietary Illuminox ™ technology platform.
-
Rakuten Medical Establishes Illuminox™ Alliance Institutes to Accelerate Development of Cancer Therapies, Announcing The National Cancer Center Japan as the First Institute to Join the Alliance
5/29/2020
Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing precision, cell-targeting investigational therapies on its Illuminox™ technology platform, established a strategic cancer research alliance network, the Illuminox Alliance Institutes (IAI), in order to advance the development of new cancer therapies.
-
Rakuten Medical to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/10/2020
Rakuten Medical, Inc. (RMI) a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, will present at the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020, in San Francisco.
-
Rakuten Medical appoints David Chao and Kentaro Hyakuno to its Board of Directors, Welcomes new CFO and General Counsel to Executive Leadership Team
11/11/2019
Rakuten Medical has appointed two new directors to the company's Board: David Chao, co-founder and General Partner of DCM Ventures; and Kentaro Hyakuno, Chief Operating Officer and Group Executive Vice President of Rakuten, Inc.
-
It was another busy week for clinical trials. Here’s a look.
-
Rakuten Medical Releases New, Post-hoc Analysis of Safety, Pharmacokinetic (PK), Immunogenicity and Biomarker Data from its Phase 1 & 1/2a Clinical Trials
9/30/2019
Two posters were presented during the European Society for Medical Oncology (ESMO) Congress 2019 on its RM-1929 photoimmunotherapy (PIT) treatment in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC)
-
Ecommerce Company Rakuten Invests $100 Million in Rakuten Medical, Increasing Equity Share to 22.5%
8/2/2019
Rakuten Medical was formerly called Aspyrian Therapeutics. Since launching in 2015, it has raised almost $500 million. -
Rakuten Medical Secures Additional Investment from Rakuten to Further Develop its Photoimmunotherapy Platform Capabilities
8/1/2019
Rakuten Medical, Inc., a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy (PIT) platform, has raised approximately US $100 million on July 31, 2019, i
-
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
-
Rakuten Medical Releases Phase 2a Study Data during ASCO Annual Meeting Highlighting Positive Safety Profile and Clinically Meaningful Anti-tumor Activity
6/1/2019
Rakuten Medical announces positive data results from its Phase 2a study, evaluating the safety and anti-tumor activity of RM-1929 PIT in patients with locoregional, recurrent head and neck squamous cell carcinoma.